---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Epidemiology and eligible population inputs"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Epidemiology and eligible population inputs. Topics: Company estimate of the addressable BCG-unresponsive population, Planned inclusion of papillary-only disease in the marketing application, Bladder cancer incidence and prevalence in the United States, Eligible population inputs in a published budget impact model, and 5 further topics. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/epidemiology-and-eligible-population-inputs"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Epidemiology and eligible population inputs

<a id="heading-4.2.3"></a>

## 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: eligible population inputs

No evidence found.

<a id="topic-4.2.3-2"></a>

### Company estimate of the addressable BCG-unresponsive population

> “Based on internal research derived from the National Cancer Institute Surveillance, Epidemiology, and End Results Program’s (NIH SEER) database, secondary claims data analytics and management assumptions, the BCG-unresponsive NMIBC segment may represent up to 25,000 addressable patients.”
> “Cretostimogene is currently in clinical development for the treatment of patients with high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), which potentially represents up to 150,000 addressable patients in the United States.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-4.2.3-3"></a>

### Planned inclusion of papillary-only disease in the marketing application

> “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-4.2.3-4"></a>

### Bladder cancer incidence and prevalence in the United States

| Measure | Value |
| --- | --- |
| Estimated new cases in 2026 | “84,530” |
| Estimated deaths in 2026 | “17,870” |

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

> “The rate of new cases of bladder cancer was 17.9 per 100,000 men and women per year.”
> “In 2023, there were an estimated 763,031 people living with bladder cancer in the United States.”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-4.2.3-5"></a>

### Eligible population inputs in a published budget impact model

> “In the base-case analysis, the model considered adults (aged ≥18 years) with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1. Prevalent cases were considered in Year 1 and incident cases were considered in Years 2–3.”
> “Specifically, the prevalence of bladder cancer was 0.0634% and the incidence was 0.0244%, based on US Surveillance, Epidemiology, and End Results Program (SEER) registry data”
> “a real-world study of treatment patterns and clinical outcomes of US patients with bladder cancer based on the SEER-Medicare claims data, 73.1% of all patients with bladder cancer had NMIBC and, among them, 42.3% were classified as high-risk; 16.5% of patients with high-risk NMIBC had CIS ± Ta/T1 while 83.5% had high-grade Ta/T1 only”
> “Among patients with high-risk NMIBC, 56.5% were treated with BCG”
> “and 30% of those were unresponsive to BCG”
> “Among adults with high-risk, BCG-unresponsive NMIBC, 92.6% and 81.2% remained alive at Years 2 and 3, respectively, based on an analysis of SEER Medicare claims data”
> “An annual recurrence rate of 55.1% was used”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.3-6"></a>

### Eligible patients per one million health plan members

> “In a hypothetical health plan with one million lives, the number of adults with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1 who were eligible for nadofaragene firadenovec was estimated to be 5.5 in Year 1, 4.9 in Year 2, and 4.5 in Year 3 (Table 1).”
> “In Scenario analysis 1, which considered incident bladder cancer cases only, the size of the target population was estimated to be 2.1 patients in each year.”
> “In Scenario analysis 2, when considering the broader population eligible for nadofaragene firadenovec to the pooled population of CIS ± Ta/T1 plus Ta/T1 only, the size of the target population was estimated to be 33.2 patients in Year 1, 29.7 in Year 2, and 27.5 in Year 3.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.3-7"></a>

### Projected market shares in a published budget impact model

> “Market shares of nadofaragene firadenovec were projected to be 2% in Year 1, 6% in Year 2, and 18% in Year 3, according to market research by Ferring Pharmaceuticals (data on file).”
> “Specifically, the market share of gemcitabine/docetaxel in Year 1 was based on Yang et al. (2024) (7.1%)”
> “In the absence of nadofaragene firadenovec market entry, the market shares of existing treatments were proportionally scaled to sum to 100% while maintaining their relative distribution.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.3-8"></a>

### Eligible prevalent population and uptake in the ICER review

> “The National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER) estimates that prevalence of bladder cancer was 712,614 people in the US in 2017.”
> “Kirkali et al. estimated that approximately 70% of bladder cancers present as NMIBC, with approximately 70% classified as Ta, 20% as T1, and 10% as CIS.”
> “We assumed that T1 and CIS are considered high-grade disease while 10% of Ta cancers are considered high grade.”
> “the proportion of patients who are BCG-unresponsive/refractory, we assumed that approximately 38% will be classified as BCG non-responders.”
> “Applying these proportions to the estimated prevalent NMIBC population (712,614), we arrived at an estimate of 70,135 individuals as the eligible population for these treatments, with 73% (51,180) being Ta and T1 patients and 27% (18,956) being CIS patients.”
> “Among these eligible patients, we assumed a 20% uptake each year over five years, or 14,027 patients per year.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.3-9"></a>

### Proportion of patients unresponsive to BCG

> “However, more than 40% of patients with high-risk NMIBC do not respond to initial BCG treatment, and many experience loss of response over time”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “Despite treatment with intravesical Bacillus Calmette-Guérin (BCG) therapy, more than half of patients with NMIBC develop recurrence or progression within 1–2 years and up to 40% eventually become unresponsive to BCG”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.3-10"></a>

### Proportion of patients who decline or are ineligible for radical cystectomy

> “up to 80% of patients decline or are ineligible for the procedure due to associated morbidity, mortality, or quality of life concerns”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
